Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 12 2021
Historique:
received: 05 04 2020
accepted: 14 12 2021
entrez: 30 12 2021
pubmed: 31 12 2021
medline: 27 1 2022
Statut: epublish

Résumé

Information on microbiota dynamics in pulmonary tuberculosis (TB) in Africa is scarce. Here, we sequenced sputa from 120 treatment-naïve TB patients in Uganda, and investigated changes in microbiota of 30 patients with treatment-response follow-up samples. Overall, HIV-status and anti-TB treatment were associated with microbial structural and abundance changes. The predominant phyla were Bacteroidetes, Firmicutes, Proteobacteria, Fusobacteria and Actinobacteria, accounting for nearly 95% of the sputum microbiota composition; the predominant genera across time were Prevotella, Streptococcus, Veillonella, Haemophilus, Neisseria, Alloprevotella, Porphyromonas, Fusobacterium, Gemella, and Rothia. Treatment-response follow-up at month 2 was characterized by a reduction in abundance of Mycobacterium and Fretibacterium, and an increase in Ruminococcus and Peptococcus; month 5 was characterized by a reduction in Tannerella and Fusobacterium, and an increase in members of the family Neisseriaceae. The microbiota core comprised of 44 genera that were stable during treatment. Hierarchical clustering of this core's abundance distinctly separated baseline (month 0) samples from treatment follow-up samples (months 2/5). We also observed a reduction in microbial diversity with 9.1% (CI 6-14%) of the structural variation attributed to HIV-status and anti-TB treatment. Our findings show discernible microbiota signals associated with treatment with potential to inform anti-TB treatment response monitoring.

Identifiants

pubmed: 34966183
doi: 10.1038/s41598-021-04271-y
pii: 10.1038/s41598-021-04271-y
pmc: PMC8716532
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

24486

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107743/Z/15/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P007767/1
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Int J Tuberc Lung Dis. 2014 May;18(5):541-6
pubmed: 24903790
J Infect. 2003 Nov;47(4):317-21
pubmed: 14556756
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
mSystems. 2017 Jan 3;2(1):
pubmed: 28066818
Clin Microbiol Rev. 2016 Oct;29(4):915-26
pubmed: 27608937
BMC Microbiol. 2012 Nov 23;12:276
pubmed: 23176186
Microbiome. 2014 Aug 25;2:29
pubmed: 25225609
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
BMC Infect Dis. 2019 Oct 30;19(1):923
pubmed: 31666021
PLoS One. 2013 Dec 13;8(12):e83445
pubmed: 24349510
mSystems. 2015 Dec 22;1(1):
pubmed: 27822518
Chem Biol. 1998 Oct;5(10):R245-9
pubmed: 9818143
PLoS Pathog. 2013 Jan;9(1):e1003057
pubmed: 23326226
PLoS One. 2013;8(1):e54574
pubmed: 23365674
Eur Respir J. 2011 Feb;37(2):376-83
pubmed: 20516049
PLoS One. 2011 May 09;6(5):e19565
pubmed: 21573015
Sci Rep. 2018 Apr 10;8(1):5724
pubmed: 29636512
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):122-128
pubmed: 31110428
Front Physiol. 2017 Nov 17;8:822
pubmed: 29204120
Nature. 2019 May;569(7758):641-648
pubmed: 31142853
Tuberculosis (Edinb). 2016 Sep;100:89-94
pubmed: 27553415
BMC Res Notes. 2012 Jan 19;5:44
pubmed: 22260090
mBio. 2018 Sep 18;9(5):
pubmed: 30228238
Expert Rev Respir Med. 2016 Jun;10(6):643-54
pubmed: 27030924
PLoS Comput Biol. 2017 Feb 21;13(2):e1005404
pubmed: 28222096
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
Lancet. 2014 Feb 1;383(9915):424-35
pubmed: 24176144
Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1205-10
pubmed: 27142586
Sci Rep. 2017 Sep 7;7(1):10767
pubmed: 28883399
Science. 2016 Apr 29;352(6285):560-4
pubmed: 27126039
Environ Microbiol. 2017 Apr;19(4):1450-1462
pubmed: 28078754

Auteurs

David Patrick Kateete (DP)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda. david.kateete@mak.ac.ug.

Monica M Mbabazi (MM)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Faith Nakazzi (F)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Fred A Katabazi (FA)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Edgar Kigozi (E)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Willy Ssengooba (W)

BSL-3 Mycobacteriology Laboratory, Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Lydia Nakiyingi (L)

Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Infectious Diseases Institute, Makerere University College of Health Sciences, Mulago Hospital Complex, Kampala, Uganda.

Sharon Namiiro (S)

Makerere University Lung Institute, Makerere University College of Health Sciences, Kampala, Uganda.

Alphonse Okwera (A)

TB Clinics, Mulago National Referral Hospital, Kampala, Uganda.

Moses L Joloba (ML)

Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda.

Adrian Muwonge (A)

Division of Genetics and Genomics, The Roslin Institute, University of Edinburgh, Edinburg, UK. adrian.muwonge@roslin.ed.ac.uk.
Division of Infection and Immunity, The Roslin Institute, University of Edinburgh, Edinburg, UK. adrian.muwonge@roslin.ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH